HeyJaredLauren Dembeck
- Indexed articles, last 90 days
- 28
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Oncology Nurse Advisor
- Top 5M sites
- Earliest in this view
- Jul 8, 2026
Latest articles
Bipolar TURP Remains Benchmark for Urinary Outcomes in BPH Procedures (opens the original)
Read excerpt
No contemporary surgical or minimally invasive treatment significantly outperforms bipolar transurethral resection of the prostate (bTURP) for urinary efficacy at approximately 12 months in men with benign prostatic obstruction, although holmium laser enucleation of the prostate (HoLEP) may offer greater durability, according to findings published in International Urology and Nephrology. “Although [TURP] has been the surgical gold standard, its associated morbidity drove the development of minim
Peyronie Disease Trials Reveal Significant Placebo Injection Response (opens the original)
Read excerpt
Intralesional placebo injections are associated with an average reduction of approximately 5 degrees in penile curvature in men with Peyronie disease (PD), suggesting non-pharmacologic, procedure-related effects, investigators reported in The Journal of Sexual Medicine. These effects should be considered when evaluating the efficacy of active injection therapies in placebo-controlled trials. “Understanding the placebo response is essential for the accurate interpretation of treatment efficacy an
High Decipher Score Linked to Major Progression During Prostate Cancer Active Surveillance (opens the original)
Read excerpt
A high Decipher genomic risk score is associated with greater risk for major pathological progression among men with lower-risk prostate cancer undergoing active surveillance, according to findings published in European Urology Oncology. Shee et al wrote that these results suggest genomic testing may help tailor surveillance intensity. “Active surveillance for prostate cancer requires periodic laboratory and imaging tests and prostate biopsy to avoid morbidity associated with definitive treatmen
Epcoritamab Plus R2 Improves Response and PFS in R/R Follicular Lymphoma (opens the original)
Read excerpt
Epcoritamab combined with lenalidomide and rituximab (R2) significantly improves response rates and progression-free survival (PFS) compared with R2 alone in patients with relapsed or refractory follicular lymphoma (R/R FL), according to phase 3 findings presented at the Society of Hematology Oncology 2026 Annual Meeting. Epcoritamab is a CD3 × CD20 bispecific antibody approved as monotherapy for patients with R/R FL after at least 2 prior lines of therapy. In the earlier phase 1b/2 EPCORE NHL-2
Disease-Free Survival May Be a Valid Overall Survival Surrogate in Localized RCC Trials (opens the original)
Read excerpt
Disease-free survival (DFS) appears to be a valid trial-level surrogate for overall survival (OS) in patients with localized renal cell carcinoma (RCC), according to results from a meta-analysis of randomized controlled trials published in Cancer. DFS is commonly used as a primary endpoint in trials of adjuvant therapy for localized RCC because demonstrating an OS benefit requires prolonged follow-up. However, the relationship between treatment effects on DFS vs OS has not been firmly establishe
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Oncology Nurse Advisor, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.